David Daya

Senior Vice President, Franchise Head, Oncology Business Unit

David Daya was appointed Senior Vice President, Franchise Head, Oncology Business Unit in October 2021. In this role, David leads Ipsen’s growing oncology franchise in the U.S., providing vision, leadership and oversight for the commercial team. He is responsible for the overall development and implementation of long-term strategic growth initiatives for the oncology franchise.

David joined Ipsen in 2019 as Vice President and General Manager of the Nordics and Baltics, based in Sweden, where under his leadership the business grew more than 10% in 2020 and market share grew across all specialty brands. Prior to joining Ipsen, David spent more than 17 years at Eli Lilly. In his last role at Lilly, he served as the Oncology Therapeutic Area Head for International Markets. He also worked across various international commercial roles, living and working in Canada and Belgium.

David is from Beirut, Lebanon and holds a dual degree in Biology and Chemistry from the Lebanese American University and a Business Management degree from McGill University.

Our mission?

To improve patients’ lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care. We help patients through our expertise in oncology, neuroscience, and rare disease.

Find out more about us or see other members of our leadership team.

About

Products and partnerships

Our products

Our mission is to improve patients’ lives.

See our products

Partnering

Access our development and commercialization teams. We take bold steps to translate your science and innovations into solutions that make a difference for patients in need.

See more on partnering

Products and partnerships

What’s happening now?

See the latest
©2022 Ipsen Biopharmaceuticals, Inc. NON-US-003140 April 2022